| Project Title |
Contact |
| Holographic Inspection of Bio-Pharmaceutical Processes: Optical Monitoring of Cell Growth In the Production Line |
Prof John Sheridan |
| Synthesis and Biological Evaluation of Bioorganometallic Antibiotics |
Dr Matthias Tacke |
| Synthesis and Biological Evaluation of Bioorganometallic Anticancer Drugs |
Dr Matthias Tacke |
| Application of the catalytic asymmetric alpha-arylation of ketones in total synthesis |
Prof Pat Guiry |
| Synthesizing specific inhibitors of Falcipain 3 a drug target for treating malaria |
Prof Paul Malthouse |
| Synthesizing specific glyoxal inhibitors of Urokinase Plasminogen Activator(uPA) a drug target for treating breast cancer |
Prof Paul Malthouse |
| Determining warhead potency with protease inhibitors |
Prof Paul Malthouse |
| Synthesizing isotopically enriched protease inhibitors and enzymes for NMR studies of protease - inhibitor interactions |
Prof Paul Malthouse |
| Development of skincare products from frog skin peptides |
Dr Chandralal Hewage |
| NMR and molecular modeling studies of incretin hormones |
Dr Chandralal Hewage |
Structural studies of antimicrobial peptides
|
Dr Chandralal Hewage |
| Natural products for diabetic therapy |
Dr Chandralal Hewage |
| Diabetic Kidney Disease |
Dr Tara McMorrow |
| Renal Toxicology and Toxicity Testing |
Dr Tara McMorrow |
| Catalytic Asymmetric Grignard reaction |
Prof Declan Gilheany |
| P-Stereogenic components of ProTide drugs |
Prof Declan Gilheany |
| Alternative, in vitro testing strategies for screening pharmaceuticals and chemicals for potential developmental toxicity: New horizons with a human induced pluripotent stem cell model (iPSTox). |
Dr Helen Gallagher |
| Development of Catalysts for Stereoselective Glycosylations |
Dr Eoghan McGarrigle |
| Organocatalysts for the Synthesis of 2-DeoxySugars |
Dr Eoghan McGarrigle |
| Differential hypoxia signaling in breast cancer: potential therapeutic target |
Dr Alex Cheong |
| Molecular simulation studies of protein-ligand binding and nanomedicine via structure-based drug design |
Dr Niall English |
| Development of new photodynamic therapeutic agents. |
Prof Donal O'Shea |
